• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

SNS-314

CAS No. 1146618-41-8

SNS-314 ( SNS-314 Mesylate | SNS314 | SNS 314 )

产品货号. M10517 CAS No. 1146618-41-8

SNS-314 是一种有效的选择性泛 Aurora 激酶抑制剂,Aurora A 和 Aurora B 的 IC50 分别为 9 和 31 nM。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
2MG ¥429 有现货
5MG ¥680 有现货
10MG ¥1037 有现货
25MG ¥2001 有现货
50MG ¥2770 有现货
100MG ¥4026 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    SNS-314
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    SNS-314 是一种有效的选择性泛 Aurora 激酶抑制剂,Aurora A 和 Aurora B 的 IC50 分别为 9 和 31 nM。
  • 产品描述
    SNS-314 is a potent, selective pan-Aurora kinase inhibitor with IC50 of 9 and 31 nM for Aurora A and Aurora B, repectively; demonstrates broad activity in vitro against multiple human cancer cell lines and exhibits significant in vivo activity against a wide range of tumor xenograft models; shows additive antiproliferative effects with carboplatin, gemcitabine, 5-FU, daunomycin, and SN-38 both in vitro and in vivo.Solid Tumors Phase 1 Discontinued(In Vitro):SNS-314 blocks proliferation in a broad panel of tumor cell lines (HCT116, A2780, PC-3, HeLa, MDA-MB-231, H-1299, and HT29) with IC50 values ranging from 1.8 nM in A2780 ovarian cancer cells to 24 nM in HT29 colon cancer cells.(In Vivo):In the HCT116 human colon cancer xenograft model, administration of 50 and 100 mg/kg SNS-314 leads to dose-dependent inhibition of histone H3 phosphorylation for at least 10 h. SNS-314 shows significant tumor growth inhibition in a dose dependent manner under a variety of dosing schedules including weekly, bi-weekly, and 5 days on/9 days off.
  • 体外实验
    SNS-314 blocks proliferation in a broad panel of tumor cell lines (HCT116, A2780, PC-3, HeLa, MDA-MB-231, H-1299, and HT29) with IC50 values ranging from 1.8 nM in A2780 ovarian cancer cells to 24 nM in HT29 colon cancer cells.
  • 体内实验
    In the HCT116 human colon cancer xenograft model, administration of 50 and 100 mg/kg SNS-314 leads to dose-dependent inhibition of histone H3 phosphorylation for at least 10 h. SNS-314 shows significant tumor growth inhibition in a dose dependent manner under a variety of dosing schedules including weekly, bi-weekly, and 5 days on/9 days off.
  • 同义词
    SNS-314 Mesylate | SNS314 | SNS 314
  • 通路
    Cell Cycle/DNA Damage
  • 靶点
    Aurora Kinase
  • 受体
    AuroraA|AuroraB|AuroraC
  • 研究领域
    Cancer
  • 适应症
    Solid Tumors

化学信息

  • CAS Number
    1146618-41-8
  • 分子量
    527.04
  • 分子式
    C19H19ClN6O4S3
  • 纯度
    >98% (HPLC)
  • 溶解度
    10 mM in DMSO
  • SMILES
    CS(=O)(=O)O.C1=CC(=CC(=C1)Cl)NC(=O)NC2=NC=C(S2)CCNC3=NC=NC4=C3SC=C4
  • 化学全称
    Urea, N-(3-chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]-, methanesulfonate (1:1)

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Oslob JD, et al. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4880-4. 2. VanderPorten EC, et al. Mol Cancer Ther. 2009 Apr;8(4):930-9. 3. Arbitrario JP, et al. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17.
产品手册
关联产品
  • Pilaralisib

    Pilaralisib 是一种口服小分子,可选择性抑制磷酸肌醇 3 激酶 (PI3K) 的活性。

  • SP-146

    SP-146 是一种选择性、有效且非 ATP 竞争性 Aurora B 抑制剂 (IC50 : 0.316 nM)。

  • Phthalazinone pyrazo...

    Phthalazinonepyrazol 是一种有效的、选择性的、口服生物可利用的 Aurora-A 激酶抑制剂。 Aurora-A 在多种肿瘤类型中过度表达并表现出致癌活性。